Acro Biotech

Executive Summary

Acro Biotech is a San Diego-based private manufacturer of rapid diagnostic tests, specializing in lateral flow immunoassays for respiratory infections, drugs of abuse, cardiac markers, and women's health. Founded in 2015, the company operates from an ISO 13485:2016 certified facility and markets its products internationally. As a privately held firm, Acro Biotech does not disclose financials, but its focus on affordable, point-of-care diagnostics positions it well in the growing rapid testing market, which is projected to exceed $20 billion by 2028. The company's broad product portfolio and international presence mitigate risks, though competition from larger players and regulatory hurdles remain challenges. Near-term growth is expected to be driven by the post-pandemic demand for respiratory testing and expansion into emerging markets. However, the lack of public funding and limited visibility into pipeline progress temper conviction.

Upcoming Catalysts (preview)

• Q3 2026FDA Clearance for a Multiplex Respiratory Panel65% success
• Q2 2026Distribution Agreement for Expansion into Southeast Asia70% success
• Q4 2026Launch of a Cardiac Marker Rapid Test (e.g., troponin)55% success